13
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T2503 | PAC-1 | Procaspase activating compound 1 | Apoptosis , Caspase , Autophagy |
PAC-1 (Procaspase activating compound 1) has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers, among others. | |||
T78105 | PAC1R antagonist 1 | PACAP | |
PAC1R antagonist 1 is an orally active PAC1 receptor antagonist that inhibits abnormal pain induced by pituitary adenylate cyclase-activating polypeptide (PACAP) and nerve damage, and may be used in the study of neoplasm... | |||
T18603 | PROTAC BRD4 degrader for PAC-1 | Others | |
PROTAC BRD4 degrader for PAC-1 (compound 5) is a chimeric BET degrader GNE-987 conjugated with a disulfide-containing linker[1]. This PROTAC-linker conjugate specifically targets and degrades BRD4, enabling selective pro... | |||
TP1618L | PACAP-38 (31-38), human, mouse, rat acetate | PACAP-38 (31-38), human, mouse, rat acetate(138764-85-9 Free base) | PACAP |
PACAP-38 (31-38), human, mouse, rat acetate is an activator of PAC1 receptor. PACAP-38 (31-38), human, mouse, rat acetate demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY an... | |||
T41005 | PA-8 | PACAP | |
PA-8 is a small molecule receptor antagonist for PACAP Type I (PAC1) that is selective, effective, and orally active. PA-8 inhibits PacAP-induced CREB phosphorylation at PAC1- receptors, but does not inhibit VPAC1- or vp... | |||
T76949 | Zelminemab | ||
Zelminemab (AMG-301) is a human monoclonal antibody designed to target and inhibit the PACAP type I (PAC1) receptor [1]. | |||
TP2071 | Bay 55-9837 | ||
Selective VPAC2 receptor agonist (EC50 values are 0.4, 100 and >1000 nM for VPAC2, VPAC1 and PAC1, respectively in a cAMP accumulation assay; IC50 values are 60, 8700 and >10000 nM for VPAC2, VPAC1 and PAC1, respectively... | |||
T24585 | PA-9 | PA 9 | |
PA-9 is the first small-molecule PAC1 receptor antagonist. | |||
T81891 | M65 | ||
M65 is a PAC1 receptor-specific antagonist that inhibits the secretion of atrial natriuretic peptide (ANP) [1]. | |||
T29140 | VU0652925 | VU 0652925,BMS-3,VU-0652925,BMS3,BMS 3 | |
VU0652925 is a PAR4 antagonist. VU0652925 has a P-sel IC50 of 39.2 pM (-pIC50±SEM: 10.41±0.04) and a PAC1 IC50 of 43.0 pM (-pIC50±SEM: 10.4±0.04). | |||
TP1069 | PACAP (1-27), human, ovine, rat TFA | PACAP 1-27 TFA | |
PACAP (1-27), human, ovine, rat TFA (PACAP 1-27 TFA) is an N-terminal fragment of pacap-38 and an effective PACAP receptor antagonist. The IC50s for rat PAC1, rat VPAC1 and human VPAC2 are 3nm, 2nm and 5nm respectively. | |||
T36427 | PACAP (6-27) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt) | PACAP | |
Pituitary adenylate cyclase-activating peptide (PACAP) (6-27) is a PACAP receptor antagonist with IC50 values of 1,500, 600, and 300 nM, respectively, for rat PAC1, rat VPAC1, and human VPAC2 recombinant receptors expres... | |||
TP1878 | PACAP (1-38), human, ovine, rat | Pituitary Adenylate Cyclase Activating Polypeptide 38,PACAP 1-38 | PACAP |
PACAP (1-38), human, ovine, rat (Pituitary Adenylate Cyclase Activating Polypeptide 38) is a neuropeptide with 38 amino acid residues. |